CD8A and neoplasm: In this context, neither FOXP3 + PD-1/CD8 nor CD32B/CD19 remained independently associated with DFS, whereas higher CD32B/CD19 did retain an association with poorer OS, while EGFR mutations and platinum-based therapy were each linked to improved survival, underscoring the dominant influence of tumor stage, molecular profile, and systemic treatment on outcome.